Current stock page

Catalysts

REPL Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

REPLReplimune Group, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$21.89−$0.09 (−0.41%)

Latest quote

  • Momentum
    97
  • Value
    —
  • Quality
    35
  • Risk resilience
    26
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 2, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 60/100

Momentum 97/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 30.13%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 97/100AIQ Edge 10/10 Sector Leader
Beat rate
13%
1 of 8 reported periods
Average surprise
-2.1%
Across covered historical reports
Latest result
+31.1%
Oct 28, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 28, 2026—-$0.78-$0.54+31.1%$1M—
Aug 14, 2026—-$0.69-$0.72-3.7%$13.6M—
Jun 29, 2026—-$0.73-$0.76-4.1%$3.57M—
Feb 3, 2026—-$0.77-$0.77-0.2%$428.57K—
Nov 6, 2025—-$0.87-$0.90-3.4%$714.29K—
Aug 7, 2025—-$0.83-$0.95-14.5%$500K—
May 22, 2025—-$0.75-$0.82-9.3%—$1.47M
Feb 12, 2025—-$0.70-$0.79-12.9%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
7
Buy
1
Sell
12-month analyst target
$30.00
+37.05% versus current price
Based on 8 analyst observations. Targets are estimates, not predictions.
Low target
$29.00
+32.48% vs latest price
Average target
$30.00
+37.05% vs latest price
High target
$31.00
+41.62% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 2, 2027

Next known earnings or reporting date.

EPS estimate-$0.57

Current analyst expectation for the upcoming report.

Revenue estimate$12.03M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score97

Where event reaction would show up first.

AIQ score60/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
8
Average target
$30.00
Target upside
37.05%
Target range
$29.00 - $31.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Oct 28, 2026

Replimune anticipates permanent J-code by April 2027 as TUDRIQEV launch metrics build (NASDAQ:REPL)

Replimune Q2 FY2027 earnings call: TUDRIQEV launch momentum, early melanoma uptake, cash runway, and key risks.

seekingalpha.com · Oct 28, 2026

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDTCompany ParticipantsArleen GoldenbergSushil Patel - CEO &...

gurufocus.com · Oct 28, 2026

Q2 2027 Replimune Group, Inc. Earnings Call Transcript

Oct 28, 2026 / 12:00PM GMTOperator Good day, and thank you for standing by. Welcome to the Replimune's second-quarter fiscal 2027 earnings conference call. (Ope

seekingalpha.com · Oct 13, 2026

Replimune Group: A Hold Until TUDRIQEV’s Commercial Potential Becomes Clear (NASDAQ:REPL)

With limited cash runway and significant competition, Replimune remains a high-risk investment with uncertain near-term upside. Click for more on REPL.

gurufocus.com · Sep 15, 2026

Replimune Group Inc Annual Shareholders Meeting Transcript

Sep 15, 2026 / 12:30PM GMTOperator Hello and welcome to the 2026 Annual Meeting of Stockholders of Replimune Group, Inc. Please note that today's meeting is bei

Open full news and sentiment

REPL Catalysts FAQ

What are the next catalysts for REPL stock?

REPL's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move REPL stock?

Upcoming events that could move REPL include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could REPL's next earnings report affect the stock?

REPL's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive REPL stock higher?

REPL could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt REPL stock?

REPL could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.